NAI500

A bridge between

    • NAI500NAI500
      ·07-11 19:09

      Gene editing stock NTLA is poised to rise

      Gene-editing company $Intellia Therapeutics(NTLA)$ has just released some new data that shows the company has the ability to continue to lead the gene-editing field. While there is still much work to be done to confirm and profit from Intellia's new findings, none of its peers have been able to cross the bridge.New proof-of-concept stuff? Intellia's main goal is to develop gene editing therapies that can correct congenital genetic problems. The lead project NTLA-2001 aims to treat a rare disease called transthyroxin amyloidosis (ATTR) by knocking out the gene for a dysfunctional protein that causes heart failure and shortness of breath.Management forecasts that the market for ATTR drugs will reach $11 billion a year by 2029, which represents signi
      345Comment
      Report
      Gene editing stock NTLA is poised to rise
    • NAI500NAI500
      ·07-10 18:56

      Tech Titans Drive US Stocks: Only 17% of S&P 500 Outperform Index

      Over the past 30 days, the $SPDR S&P 500 ETF Trust(SPY)$ has soared more than 3.5%, which is pretty dazzling considering signs of a slowing economy. Data AnalysisYet underlying investors' optimism is a worrying fact: only 17% of $S&P 500(.SPX)$ stocks have beaten the index over the past month. That’s a historic low! Let’s crunch the numbers: out of the S&P 500 stocks, a mere 85 have outperformed the index over the past 30 days. That’s the lowest it's been in at least a decade. By comparison, over the past ten years, the average has been around 49%, hitting over 50% in the latter half of 2022, late 2023, and early 2024.Bottom line? The US stock market’s surge is being driven by just a handful of
      5301
      Report
      Tech Titans Drive US Stocks: Only 17% of S&P 500 Outperform Index
    • NAI500NAI500
      ·07-09

      Volkswagen bets $5 billion on Rivian: Game-changer or alarm bell?

      With AI now the talk of the town, it’s turbocharging the race toward smart electric cars. Whether it’s newbies like $Rivian Automotive, Inc.(RIVN)$ or the old guard, everyone wants a piece of the action in this century-old car revolution. $Volkswagen AG(VLKAY)$ just dropped a bombshell, pumping a cool $5 billion into Rivian and agreeing to cook up a tech venture together. In return, VW gets dibs on Rivian’s software and electric car tech, teaming up to whip out "next-gen" battery-powered wheels and software with partners. "Tesla’s nemesis" ?Post-announcement, Rivian’s stock skyrocketed over 50% in after-hours trading, clawing back half its year-to-date losses.Once hailed as "
      744Comment
      Report
      Volkswagen bets $5 billion on Rivian: Game-changer or alarm bell?
    • NAI500NAI500
      ·07-08

      Trump Trade Soars: Assets Rally on Wall St!

      Wall Street is buzzing with "Trump trades" as discussions about President Biden's potential re-election bid heat up. Traders are adjusting portfolios, tweaking assets like the dollar, bonds, and more in anticipation of a possible return to the White House by Trump.Experts predict a Trump re-election could spur trades benefiting from loose fiscal policies and escalated trade protectionism. This includes a stronger dollar, higher US bond yields, and upticks in sectors like banking, healthcare, and energy.1.Dollar SignalThe dollar is the quickest to react in these "Trump trades," strengthening just hours after recent debates. Trump's proposed tax cuts and hefty tariffs on imports from China and other countries are key factors.Goldman Sachs' chief economist Jan Hatzius warns that these tariffs
      1.22K1
      Report
      Trump Trade Soars: Assets Rally on Wall St!
    • NAI500NAI500
      ·07-08

      Biotech Picks: AMGN, VRTX, VKTX Over Lilly

      A few years back, $Eli Lilly(LLY)$ wasn't the hottest ticket in biopharma. But today, it's a juggernaut in global healthcare. So, is Eli Lilly still the top pick for healthcare investors? Let's check out three biotech stocks worth buying:1. $Amgen(AMGN)$ Eli Lilly's stock has surged over 50% this year, while Amgen's gains have been in the single digits. Amgen even reported a net loss in Q1 2024 under GAAP.But where Amgen really shines is valuation—it beats Eli Lilly hands down. Amgen's forward P/E ratio is less than 16.2x, while Lilly's is a hefty 66.7x. And on dividends, Amgen trumps Lilly with a forward dividend yield of 2.9% versus Lilly's paltry 0.6%.2. $Vertex Ph
      1.35K1
      Report
      Biotech Picks: AMGN, VRTX, VKTX Over Lilly
    • NAI500NAI500
      ·07-05

      Among Buffett's Top 7 Holdings, Only AAPL Outpaces S&P 500

      Berkshire Hathaway $Berkshire Hathaway(BRK.B)$ $Berkshire Hathaway(BRK.A)$ 's top seven holdings are $Apple(AAPL)$ $Bank of America(BAC)$ $American Express(AXP)$ $Coca-Cola(KO)$ $Chevron(CVX)$ $Occidental(OXY)$ $The Kraft Heinz Company(KHC)$.Berkshire's seven largest holdings all account for at least 2% of the fund's total holdings, giving them a combined weighting of about 81%. Of those, only one has substantially
      7501
      Report
      Among Buffett's Top 7 Holdings, Only AAPL Outpaces S&P 500
    • NAI500NAI500
      ·07-04

      Forget Nvidia: Wall Street's Betting Big on AMD

      $NVIDIA Corp(NVDA)$ might be hogging the spotlight when it comes to AI's money-making magic, but this industry's expanding faster than a kid on a sugar rush, and $Advanced Micro Devices(AMD)$ 's right there, stealing the show. They're not just crafting datacenter chips to give Nvidia a run for its money; they're also nabbing a prime spot in AI's hot seat.AMD's all about AI!Think AMD's just about PlayStation 5s and Xbox Series Xs? Think again! They've been churning out chips that power our favorite gadgets, even $Tesla Motors(TSLA)$ 's infotainment systems. But now, they're turning their sights on AI – and they're dead serious about it.AMD sees AI as the biggest ga
      1.84K3
      Report
      Forget Nvidia: Wall Street's Betting Big on AMD
    • NAI500NAI500
      ·07-03

      The S&P 500 will fall 23% by the end of the year!

      $S&P 500(.SPX)$ might keep hitting new highs, but hold your horses! Marko Kolanovic, the chief market strategist at JPMorgan, and his crew are predicting a wild ride to the tune of a 23% crash, landing the index at 4,200 by year's end. That's a nosedive from last Thursday's close of 5,483. Why? A slowing US economy and earnings downgrades are like two anchors dragging the market down.Now, you'd think Wall Street's big shots like $Goldman Sachs(GS)$ $Citigroup(C)$ $Bank of America(BAC)$ are all singing the same bullish tune, steadily hiking their S&P 500 targets for the year. But Marko's got a different beat. His year-e
      98Comment
      Report
      The S&P 500 will fall 23% by the end of the year!
    • NAI500NAI500
      ·07-01

      S&P 500 Rises, But Pharma Stock ABBV Outpaces

      Since the Fed started hiking interest rates in 2022, pharma stocks in the US market haven't been the talk of the town. Their reliance on high-risk innovations to create shareholder value is the core reason.But $AbbVie(ABBV)$ , a pharma stock, is an outlier. Over the past 12 months, its total return, including dividends, has hit 30%, even outpacing the $S&P 500(.SPX)$ 's over 27%.Now, the question is, can this pharma stock keep outperforming the market?Despite AbbVie's strong recent performance, its forward P/E ratio is still just 15.2, significantly lower than the S&P 500's 22.6.Why is AbbVie's stock so cheap? Well, it's undergoing a transformation in its product portfolio. With the sharp drop in
      185Comment
      Report
      S&P 500 Rises, But Pharma Stock ABBV Outpaces
    • NAI500NAI500
      ·06-29

      Does Long-Term US Stocks Pay Off? 15-Year Returns Say Yes

      So far in 2024, all three major U.S. stock indexes are up, including the $S&P 500(.SPX)$ up 15%, the $DJIA(.DJI)$ up 4%, and the $NASDAQ(.IXIC)$ up 19%. However, for long-term investors, returns over several years, decades or even decades are the key. The question now is, will you make money investing in U.S. stocks over the long term? What is the return?Here are the returns of the three major U.S. stock indexes over the past 15 years:1. $S&P 500(.SPX)$ :15-year return 495% (12.6% annual return)The S&P 500 tracks 500 large and profitable U.S. companies, and the index is weighted by market capitalization, mea
      255Comment
      Report
      Does Long-Term US Stocks Pay Off? 15-Year Returns Say Yes
       
       
       
       

      Most Discussed

       
       
       
       
       

      Company: TTMF Limited. Tech supported by Xiangshang Yixin.

      Email:uservice@ttm.financial